0.67
price down icon3.67%   -0.0255
after-market アフターアワーズ: .68 0.01 +1.49%
loading
前日終値:
$0.6955
開ける:
$0.703
24時間の取引高:
7.05M
Relative Volume:
0.86
時価総額:
$185.66M
収益:
$232.40M
当期純損益:
$-20.51M
株価収益率:
-8.69
EPS:
-0.0771
ネットキャッシュフロー:
$60.04M
1週間 パフォーマンス:
-16.36%
1か月 パフォーマンス:
-27.00%
6か月 パフォーマンス:
-50.37%
1年 パフォーマンス:
-77.05%
1日の値動き範囲:
Value
$0.6659
$0.7337
1週間の範囲:
Value
$0.6659
$0.8069
52週間の値動き範囲:
Value
$0.6659
$3.20

Akebia Therapeutics Inc Stock (AKBA) Company Profile

Name
名前
Akebia Therapeutics Inc
Name
セクター
Healthcare (1052)
Name
電話
617-871-2098
Name
住所
245 FIRST STREET, CAMBRIDGE, MA
Name
職員
194
Name
Twitter
@akebiatx
Name
次回の収益日
2026-11-09
Name
最新のSEC提出書
Name
AKBA's Discussions on Twitter

Compare AKBA vs TAK, TEVA, HLN, ZTS, UTHR

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
AKBA icon
AKBA
Akebia Therapeutics Inc
0.67 185.66M 232.40M -20.51M 60.04M -0.0771
TAK icon
TAK
Takeda Pharmaceutical Co Adr
19.67 62.84B 29.91B 1.30B 3.49B 0.4056
TEVA icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
41.50 48.40B 17.53B 1.58B 444.18M 1.3457
HLN icon
HLN
Haleon Plc Adr
10.13 44.55B 14.54B 2.22B 2.58B 0.4871
ZTS icon
ZTS
Zoetis Inc
79.38 32.80B 9.51B 2.64B 2.14B 6.0361
UTHR icon
UTHR
United Therapeutics Corp
533.12 22.87B 3.17B 1.29B 1.01B 27.09

Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-08-07 ダウングレード Leerink Partners Outperform → Market Perform
2025-06-04 再開されました H.C. Wainwright Buy
2025-04-28 開始されました Leerink Partners Outperform
2025-04-01 開始されました Jefferies Buy
2023-11-29 再開されました BTIG Research Buy
2023-08-28 アップグレード H.C. Wainwright Neutral → Buy
2023-05-31 アップグレード Piper Sandler Neutral → Overweight
2022-03-31 ダウングレード H.C. Wainwright Buy → Neutral
2022-03-31 ダウングレード Mizuho Buy → Neutral
2022-03-31 ダウングレード Needham Buy → Hold
2022-03-31 ダウングレード Piper Sandler Overweight → Neutral
2021-03-08 開始されました Cantor Fitzgerald Overweight
2021-01-29 ダウングレード JP Morgan Neutral → Underweight
2019-11-14 繰り返されました Needham Buy
2019-08-06 繰り返されました H.C. Wainwright Buy
2019-07-11 繰り返されました H.C. Wainwright Buy
2019-05-02 開始されました JP Morgan Overweight
2019-03-20 開始されました Citigroup Neutral
2018-09-07 再開されました Morgan Stanley Equal-Weight
2018-08-10 繰り返されました Needham Buy
2018-06-06 繰り返されました H.C. Wainwright Buy
2017-12-19 開始されました Piper Jaffray Overweight
2017-12-07 開始されました BTIG Research Buy
2017-09-15 開始されました RBC Capital Mkts Sector Perform
2017-07-10 繰り返されました H.C. Wainwright Buy
2017-04-27 繰り返されました H.C. Wainwright Buy
2017-04-27 繰り返されました Needham Buy
2016-12-27 繰り返されました H.C. Wainwright Buy
2016-12-20 繰り返されました JMP Securities Mkt Outperform
2016-11-15 開始されました Aegis Capital Buy
2016-09-29 開始されました Brean Capital Buy
2016-03-16 繰り返されました Needham Buy
2016-01-21 開始されました Credit Suisse Neutral
すべてを表示

Akebia Therapeutics Inc (AKBA) 最新ニュース

pulisher
Oct 07, 2026

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Stock Has Average Target Price of $3.90 - MarketBeat

Oct 07, 2026
pulisher
Oct 06, 2026

Akebia Therapeutics Announces Late-Breaking VOICE Trial Presentation and Posters on Akebia’s Rare Kidney Pipeline at ASN Kidney Week 2026 - Yahoo Finance

Oct 06, 2026
pulisher
Oct 02, 2026

Akebia Therapeutics, Inc. (AKBA) Stock Price, News, Quote & History - Yahoo! Finance Canada

Oct 02, 2026
pulisher
Oct 01, 2026

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Oct 01, 2026
pulisher
Oct 01, 2026

A new hire's right to buy 8,400 Akebia shares phases in over four years, if they stay. - Stock Titan

Oct 01, 2026
pulisher
Oct 01, 2026

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Oct 01, 2026
pulisher
Sep 29, 2026

Long term debt to total equity ratio of Akebia Therapeutics, Inc. – HAN:AX9 - tradingview.com

Sep 29, 2026
pulisher
Sep 28, 2026

Akebia Therapeutics, Inc. Revenue Breakdown – MUN:AX9 - TradingView

Sep 28, 2026
pulisher
Sep 26, 2026

Akebia Therapeutics to Report Third Quarter 2023 Financial Results and Discuss Recent Business Highlights - Lelezard

Sep 26, 2026
pulisher
Sep 26, 2026

Akebia Therapeutics, Inc. $AKBA Position Reduced by State Street Corp - MarketBeat

Sep 26, 2026
pulisher
Sep 22, 2026

AKBA Shares Rise On Clinical Pipeline Optimism As Anemia Drug Gains Traction - Stocktwits

Sep 22, 2026
pulisher
Sep 18, 2026

Akebia Therapeutics, Inc. (AKBA) Stock Analysis: Exploring A 337% Potential Upside - DirectorsTalk Interviews

Sep 18, 2026
pulisher
Sep 14, 2026

Akebia Therapeutics Doses First Patient in Phase 2 Ebribafusp Trial - marketscreener.com

Sep 14, 2026
pulisher
Sep 14, 2026

One trial, three rare kidney diseases: Akebia doses its first patient - Stock Titan

Sep 14, 2026
pulisher
Sep 14, 2026

Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases - Yahoo Finance

Sep 14, 2026
pulisher
Sep 14, 2026

Akebia Therapeutics Announces First Patient Dosed in Phase - globenewswire.com

Sep 14, 2026
pulisher
Sep 14, 2026

Akebia Therapeutics Announces First Patient Dosed in Phase - GlobeNewswire

Sep 14, 2026
pulisher
Sep 14, 2026

Akebia Therapeutics (NasdaqCM:AKBA) Stock Forecast & Analyst Predictions - simplywall.st

Sep 14, 2026
pulisher
Sep 12, 2026

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Given Average Recommendation of "Hold" by Brokerages - MarketBeat

Sep 12, 2026
pulisher
Sep 12, 2026

Akebia Therapeutics (NASDAQ:AKBA) Upgraded by Wall Street Zen to Hold Rating - marketbeat.com

Sep 12, 2026
pulisher
Sep 08, 2026

AKBA Initiates Coverage On WestPark Capital -- Rating Set to Buy - GuruFocus

Sep 08, 2026
pulisher
Sep 08, 2026

Akebia Therapeutics (NASDAQ:AKBA) Earns Buy Rating from Analysts at Westpark Capital - marketbeat.com

Sep 08, 2026
pulisher
Sep 03, 2026

BlackRock Inc. Buys Shares of 19,986,374 Akebia Therapeutics, Inc. $AKBA - marketbeat.com

Sep 03, 2026
pulisher
Sep 01, 2026

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Sep 01, 2026
pulisher
Sep 01, 2026

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView

Sep 01, 2026
pulisher
Sep 01, 2026

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Sep 01, 2026
pulisher
Sep 01, 2026

Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston - marketscreener.com

Sep 01, 2026
pulisher
Sep 01, 2026

Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston - GlobeNewswire

Sep 01, 2026
pulisher
Sep 01, 2026

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Sep 01, 2026
pulisher
Sep 01, 2026

Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston - Yahoo Finance

Sep 01, 2026
pulisher
Aug 29, 2026

Nantahala Capital Management LLC Takes Position in Akebia Therapeutics, Inc. $AKBA - MarketBeat

Aug 29, 2026
pulisher
Aug 26, 2026

Akebia Therapeutics (NASDAQ:AKBA) Stock Price Passes Below 200-Day Moving AverageWhat's Next? - MarketBeat

Aug 26, 2026
pulisher
Aug 22, 2026

Akebia (AKBA) Market: Slides 1.39% to $0.91 for the Current Session; Key Range: the Near-Term Reference Band Stretches From $0.86 to $0.96 on the DayRTH Profile - vinanet.vn

Aug 22, 2026
pulisher
Aug 18, 2026

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Given Average Rating of "Hold" by Analysts - MarketBeat

Aug 18, 2026
pulisher
Aug 18, 2026

Akebia Therapeutics, Inc. Revenue Breakdown – NASDAQ:AKBA - TradingView

Aug 18, 2026
pulisher
Aug 17, 2026

Piper Sandler Maintains Akebia Therapeutics(AKBA.US) With Buy Rating, Maintains Target Price $4 - Moomoo

Aug 17, 2026
pulisher
Aug 15, 2026

AKBA Q2 2026 Earnings: Narrower-Than-Expected Loss Beats Estimates by 33.18%Return On Equity - vinanet.vn

Aug 15, 2026
pulisher
Aug 10, 2026

Akebia Therapeutics CEO John P. Butler Exercises 350,000 Stock Options at $0.63 Each - Kalkine Media

Aug 10, 2026
pulisher
Aug 10, 2026

Weekly Recap: Vafseo sales surge and ebribafusp Phase 2 trial start - TradingView

Aug 10, 2026
pulisher
Aug 10, 2026

Akebia Therapeutics, Inc. $AKBA Shares Sold by Renaissance Technologies LLC - MarketBeat

Aug 10, 2026
pulisher
Aug 10, 2026

HC Wainwright Has Negative Outlook of AKBA FY2026 Earnings - MarketBeat

Aug 10, 2026
pulisher
Aug 08, 2026

Akebia Therapeutics (AKBA) AGM 2026 Summary - Quartr

Aug 08, 2026
pulisher
Aug 07, 2026

Akebia Therapeutics Price Target Announced at $1.00/Share by Leerink Partners - Moomoo

Aug 07, 2026
pulisher
Aug 07, 2026

Akebia Therapeutics Inc (AKBA) Stock News Today - TradingKey

Aug 07, 2026
pulisher
Aug 07, 2026

Akebia Therapeutics Inc (AKBA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Aug 07, 2026
pulisher
Aug 07, 2026

Akebia Therapeutics (NASDAQ:AKBA) Downgraded by Leerink Partners to "Market Perform" - MarketBeat

Aug 07, 2026
pulisher
Aug 07, 2026

Akebia Therapeutics Inc (AKBA:UR): Stock Price, Quote and News - BNN Bloomberg

Aug 07, 2026
pulisher
Aug 07, 2026

Akebia Therapeutics, Inc. (AKBA) Investor Outlook: Analyzing a 340% Potential Upside Amid Healthcare Innovation - DirectorsTalk Interviews

Aug 07, 2026
pulisher
Aug 07, 2026

AKBA Q2 2026 Earnings: Narrower-Than-Expected Loss Delivers 55.5% EPS SurpriseEarnings Season Outlook - vinanet.vn

Aug 07, 2026
pulisher
Aug 06, 2026

H.C. Wainwright Maintains Akebia Therapeutics(AKBA.US) With Buy Rating, Maintains Target Price $6 - Moomoo

Aug 06, 2026

Akebia Therapeutics Inc (AKBA) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Akebia Therapeutics Inc (AKBA) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Ostrowski Erik
SVP, CFO, CBO & Treasurer
Jun 29 '26
Sale
1.11
56,019
62,181
616,616
Ostrowski Erik
Officer
Jun 29 '26
Proposed Sale
1.11
56,019
62,220
0
Butler John P.
CEO and President
Mar 04 '26
Buy
1.25
69,270
86,588
3,367,064
Malabre Richard C
SVP, Chief Accounting Officer
Feb 02 '26
Sale
1.39
49,524
68,838
299,390
Grund Nicholas
Chief Commercial Officer
Feb 02 '26
Sale
1.39
84,829
117,912
561,750
Burke Steven Keith
SVP, Chief Medical Officer
Feb 02 '26
Sale
1.39
67,658
94,045
948,432
Rucci Carolyn M.
SVP, Chief Legal Officer
Feb 02 '26
Sale
1.39
69,772
96,983
588,378
Ostrowski Erik
SVP, CFO, CBO & Treasurer
Feb 02 '26
Sale
1.39
34,951
48,582
672,635
Butler John P.
CEO and President
Feb 02 '26
Sale
1.39
341,305
474,414
3,206,233
Ostrowski Erik
Officer
Feb 02 '26
Proposed Sale
1.39
34,951
48,739
0
$1.40
price down icon 6.04%
$4.84
price down icon 9.53%
$3.17
price down icon 0.63%
$4.965
price down icon 3.12%
$1.10
price down icon 4.35%
OGI OGI
$0.9267
price down icon 0.53%
大文字化:     |  ボリューム (24 時間):